Mylan Weighs In On Coronavirus Drug Shortage Concerns

Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business.

factory production, process, industry — Coronavirus Raising Production Issues • Source: Shutterstock

As concerns mount about the impact the ongoing coronavirus outbreak is having on active pharmaceutical ingredient (API) manufacturing in China, some of the most pressing questions on Mylan NV’s fourth quarter and full year 2019 earnings report on 27 February were not about the company’s pending debut as Viatris GMBH or on its recent performance – but on how the global generics giant expected the situation to affect drug supply.

Opening the call, CEO Heather Bresch commented that although Mylan’s business exposure in China is limited, “given the global nature of our supply chain operations and businesses, our results could potentially be impacted

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

12 May 2025

• By Mandy Jackson

Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.

Dr Reddy’s Gears For Tariffs Scenario, To Ensure No US Supply Disruption

12 May 2025

• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

09 May 2025

• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

Pharma Left Hanging After US/UK Trade Pact

09 May 2025

• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Quick Listen: Scrip’s Five Must-Know Things

12 May 2025

• By Ian Haydock

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.